More large retrospective studies are warranted to rigorously investigate the role of endocrine resistance markers (ERBB2, BCL2, and CCND1) in screening FA patients with a high recurrence risk and increased risk of breast cancer. The gene discussed is BCL2; the disease is Friedreich ataxia.